Journal List > J Korean Thyroid Assoc > v.8(1) > 1056577

Kim: Thyroid Cancer and Radiation

Abstract

Epidemiological studies have reported an increasing incidence of thyroid cancer worldwide. This phenomenon is unclear whether it is apparent increase or true increase. In Korea, the incidence rate of thyroid cancer in both men and women showed abrupt increase from 1999 through 2011. The possible reason of this increase is suggested as improved screening with sensitive diagnostic procedures. If the incidence increase is real, there are risk factors such as ionizing radiation, obesity, diabetes mellitus, genetic predisposition, hormones, iodine diet, Hashimoto's thyroiditis, and pollutants contributing to this increased incidence. Exposure to ionizing radiation is a well-known risk factor for thyroid cancer. This was verified by epidemiological studies from survivors after Hiroshima and Nagasaki and the Chernobyl accident. The studies demonstrated that the dose-response relationship seems to be linear. However, a statistically significant increase has hardly been described with exposure to low dose radiation (<100 mSv). In addition, with respect to the data on adult exposure, there was no proven radiation related increase of the thyroid cancer incidence. Therefore, a clear understanding for the pathogenesis of radiation induced thyroid cancer is essential. Like other cancers, there are several gene alterations thought to be involved in pathogenesis of sporadic thyroid cancer. Whereas, the exact pathogenesis of radiation induced thyroid cancer by genetic alteration has not been demonstrated until now. Recently, gene expression profiling by microarray analysis has been applied to investigate the possible pathogenesis.

References

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013; 965212.
crossref
2. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013; 45(1):1–14.
crossref
3. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62(2):118–28.
crossref
4. Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E, Devesa SS. Follicular thyroid cancer incidence patterns in the United States, 1980-2009. Thyroid. 2013; 23(8):1015–21.
crossref
5. Zane M, Catalano V, Scavo E, Bonanno M, Pelizzo MR, Todaro M. et al. Estrogens and stem cells in thyroid cancer. Front Endocrinol (Lausanne). 2014; 5:124.
6. Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. J Thyroid Res. 2011; 2011; 875125.
crossref
7. Chen GG, Vlantis AC, Zeng Q, van Hasselt CA. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets. 2008; 8(5):367–77.
crossref
8. Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer. 2014; 21(5):T273–83.
crossref
9. Shih SR, Chiu WY, Chang TC, Tseng CH. Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res. 2012; 2012; 578285.
crossref
10. Tamez-Perez HE, Martinez E, Quintanilla-Flores DL, Tamez-Pena AL, Gutierrez-Hermosillo H, Diaz de Leon-Gonzalez E. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. An observational study. Med Clin (Barc). 2012; 138(11):475–7.
11. Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R. et al. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid. 2014; 24(6):966–74.
12. Bosetti C, Kolonel L, Negri E, Ron E, Franceschi S, Dal Maso L. et al. A pooled analysis of case-control studies of thyroid cancer. VI. Fish and shellfish consumption. Cancer Causes Control. 2001; 12(4):375–82.
13. Bosetti C, Negri E, Kolonel L, Ron E, Franceschi S, Preston-Martin S. et al. A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (International). Cancer Causes Control. 2002; 13(8):765–75.
14. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008; 60(2):131–44.
crossref
15. Mack WJ, Preston-Martin S, Bernstein L, Qian D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol. 2002; 12(6):395–401.
crossref
16. Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Cogliano V. et al. Carcinogenicity of nitrate, nitrite, and cyanobacterial peptide toxins. Lancet Oncol. 2006; 7(8):628–9.
17. Choi WJ, Kim J. Dietary factors and the risk of thyroid cancer: a review. Clin Nutr Res. 2014; 3(2):75–88.
crossref
18. Mousavi SM, Brandt A, Sundquist J, Hemminki K. Risks of papillary and follicular thyroid cancer among immigrants to Sweden. Int J Cancer. 2011; 129(9):2248–55.
crossref
19. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P. et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009; 94(5):1612–7.
20. Sadowski SM, He M, Gesuwan K, Gulati N, Celi F, Merino MJ. et al. Prospective screening in familial nonmedullary thyroid cancer. Surgery. 2013; 154(6):1194–8.
21. Navas-Carrillo D, Rios A, Rodriguez JM, Parrilla P, Orenes-Pinero E. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings. Biochim Biophys Acta. 2014; 1846(2):468–76.
crossref
22. He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV. et al. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab. 2015; 100(1):E164–72.
23. Wang YL, Feng SH, Guo SC, Wei WJ, Li DS, Wang Y. et al. Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. J Med Genet. 2013; 50(10):689–95.
24. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S. et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007; 204(5):764–73. discussion 73-5.
25. Azizi G, Keller JM, Lewis M, Piper K, Puett D, Rivenbark KM. et al. Association of Hashimoto's thyroiditis with thyroid cancer. Endocr Relat Cancer. 2014; 21(6):845–52.
26. Kim HK, Yoon JH, Kim SJ, Cho JS, Kweon SS, Kang HC. Higher TSH level is a risk factor for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2013; 78(3):472–7.
crossref
27. Zhang Y, Guo GL, Han X, Zhu C, Kilfoy BA, Zhu Y. et al. Do Polybrominated Diphenyl Ethers (PBDEs) Increase the Risk of Thyroid Cancer? Biosci Hypotheses. 2008; 1(4):195–9.
28. Andra SS, Makris KC. Thyroid disrupting chemicals in plastic additives and thyroid health. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012; 30(2):107–51.
crossref
29. Patrick L. Thyroid disruption: mechanism and clinical implications in human health. Altern Med Rev. 2009; 14(4):326–46.
30. Wong EY, Ray R, Gao DL, Wernli KJ, Li W, Fitzgibbons ED. et al. Reproductive history, occupational exposures, and thyroid cancer risk among women textile workers in Shanghai, China. Int Arch Occup Environ Health. 2006; 79(3):251–8.
31. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and Effects of Ionizing Radiation (UNSCRAR 2008 Report to the General Assembly with Scientific Annexes C, D and E), Vol. II. New York (NY): United Nations;2011.
32. Ivanov VK, Gorski AI, Maksioutov MA, Vlasov OK, Godko AM, Tsyb AF. et al. Thyroid cancer incidence among adolescents and adults in the Bryansk region of Russia following the Chernobyl accident. Health Phys. 2003; 84(1):46–60.
33. Chernobyl ForumHealth effects of the Chernobyl accident and special health care programmes. Geneva: World Health Organization: 2006.
34. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P. Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer. 2003; 106(4):580–7.
35. Ivanov VK, Kashcheev VV, Chekin SY, Maksioutov MA, Tumanov KA, Vlasov OK. et al. Radiation-epidemiological studies of thyroid cancer incidence in Russia after the Chernobyl accident (estimation of radiation risks, 1991-2008 follow-up period). Radiat Prot Dosimetry. 2012; 151(3):489–99.
36. Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB. et al. A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst. 2006; 98(13):897–903.
37. Miyakawa M. Radiation exposure and the risk of pediatric thyroid cancer. Clin Pediatr Endocrinol. 2014; 23(3):73–82.
crossref
38. World Health Organization. Health risk assessment from the nuclear accident after the 2011 Great East Japan Earthquake and Tsunami. Geneva: World Health Organization: 2013.
39. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM. et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995; 141(3):259–77.
40. Boice JD Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006; 295(9):1060–2.
crossref
41. Furukawa K, Preston D, Funamoto S, Yonehara S, Ito M, Tokuoka S. et al. Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure. Int J Cancer. 2013; 132(5):1222–6.
42. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011; 135(5):569–77.
crossref
43. Unger K, Zurnadzhy L, Walch A, Mall M, Bogdanova T, Braselmann H. et al. RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH. Br J Cancer. 2006; 94(10):1472–7.
44. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA. et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 2004; 209(1):1–6.
45. Rabes HM, Klugbauer S. Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Recent Results Cancer Res. 1998; 154:248–64.
crossref
46. Boaventura P, Pereira D, Celestino R, Mendes A, Nakasawa T, Teixeira-Gomes J. et al. Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment. Eur J Endocrinol. 2013; 169(5):673–9.
47. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V. et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006; 91(1):213–20.
48. Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M. et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 2008; 68(17):7176–82.
49. Smida J, Salassidis K, Hieber L, Zitzelsberger H, Kellerer AM, Demidchik EP. et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer. 1999; 80(1):32–8.
50. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T. et al. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol. 2005; 205(5):558–64.
51. Tuttle RM, Lukes Y, Onstad L, Lushnikov E, Abrosimov A, Troshin V. et al. ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. Thyroid. 2008; 18(8):839–46.
52. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED. et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999; 84(11):4232–8.
53. Ory C, Ugolin N, Schlumberger M, Hofman P, Chevillard S. Discriminating gene expression signature of radiation-induced thyroid tumors after either external exposure or internal contamination. Genes (Basel). 2011; 3(1):19–34.
crossref
54. Detours V, Delys L, Libert F, Weiss Solis D, Bogdanova T, Dumont JE. et al. Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers. Br J Cancer. 2007; 97(6):818–25.
55. Port M, Boltze C, Wang Y, Roper B, Meineke V, Abend M. A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers. Radiat Res. 2007; 168(6):639–49.
crossref
56. Detours V, Wattel S, Venet D, Hutsebaut N, Bogdanova T, Tronko MD. et al. Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer. 2005; 92(8):1545–52.
57. Ugolin N, Ory C, Lefevre E, Benhabiles N, Hofman P, Schlumberger M. et al. Strategy to find molecular signatures in a small series of rare cancers: validation for radiation-induced breast and thyroid tumors. PLoS One. 2011; 6(8):e23581.
58. Ory C, Ugolin N, Levalois C, Lacroix L, Caillou B, Bidart JM. et al. Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors. Endocr Relat Cancer. 2011; 18(1):193–206.
59. Sanzari JK, Nuth M, Kennedy AR. Induction of cytokine gene expression in human thyroid epithelial cells irradiated with HZE particles (iron ions). Radiat Res. 2009; 172(4):437–43.
crossref
60. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Nuclear and Radiation Studies Board, Division on Earth and Life Studies, National Research Council of the National Academies. Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press;2006.
61. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Philadelphia, Baltimore, New York: Lippincott Williams & Wilkins;2006.
62. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol. 1988; 35:95–125.
crossref
63. Pollycove M, Feinendegen LE. Radiation-induced versus endogenous DNA damage: possible effect of inducible protective responses in mitigating endogenous damage. Hum Exp Toxicol. 2003; 22(6):290–306. discussion 307, 315-7, 319-23.
64. Rothkamm K, Kuhne M, Jeggo PA, Lobrich M. Radiation-induced genomic rearrangements formed by nonhomologous end-joining of DNA double-strand breaks. Cancer Res. 2001; 61(10):3886–93.
65. Davis S, Kopecky KJ, Hamilton TE, Onstad L. Hanford Thyroid Disease Study Team. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA. 2004; 292(21):2600–13.
66. Watase H. Association between thyroid cancer incidence and the distance from nuclear power plants in the U.S. [Master's dissertation]. Portland (OR): Oregon Health & Science Univ;2012.
67. Bollaerts K, Fierens S, Van Bladel L, Simons K, Sonck M, Poffijn A. et al. Thyroid cancer incidence in the vicinity of nuclear sites in Belgium, 2000-2008. Thyroid. 2014; 24(5):906–17.
68. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer “epidemic”–screening and overdiagnosis. N Engl J Med. 2014; 371(19):1765–7.
69. Oh EY, Jang HW, Lee JI, Kim HK, Kim SW, Chung JH. Prevalence of thyroid nodules and cancer detected by ultrasonography in healthy Korean adults: clinical features and the risk for malignancy. J Korean Thyroid Assoc. 2010; 3(2):142–8.
TOOLS
Similar articles